


Ask a doctor about a prescription for OLMESARTAN/HYDROCHLOROTHIAZIDE KRKA 20 mg/12.5 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan/Hydrochlorothiazide Krka 20 mg/12.5 mg Film-Coated Tablets EFG
olmesartan medoxomil/hydrochlorothiazide
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Olmesartan/Hydrochlorothiazide Krka contains two active substances, olmesartan medoxomil and hydrochlorothiazide, which are used in the treatment of high blood pressure (hypertension) in adults:
You will only be given Olmesartan/Hydrochlorothiazide Krka if treatment with olmesartan medoxomil alone has not controlled your blood pressure adequately. The combination of both active substances in this medicine helps to lower blood pressure more than either substance alone.
You may already be taking medicines for high blood pressure, but your doctor may want to give you Olmesartan/Hydrochlorothiazide Krka to lower it further.
High blood pressure can be controlled with medicines like Olmesartan/Hydrochlorothiazide Krka tablets. Your doctor may also have recommended that you make some changes to your lifestyle to help lower your blood pressure (e.g., lose weight, stop smoking, reduce alcohol consumption, and reduce the amount of salt in your diet). Your doctor may also have advised you to exercise regularly, such as walking or swimming. It is important to follow your doctor's advice.
Do not takeOlmesartan/Hydrochlorothiazide Krka
If you think any of these apply to you, or are unsure, do not take the tablets. Talk to your doctor and follow their advice.
Warnings and precautions
Talk to your doctor or pharmacist before you start taking Olmesartan/Hydrochlorothiazide Krka.
Before taking the tablets, tell your doctorif you have any of the following health problems:
Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g., potassium) in your blood at regular intervals.
Also, read the information under the heading "Do not take Olmesartan/Hydrochlorothiazide Krka".
Your doctor may want to see you more often and do some tests if you have any of these problems.
Contact your doctor if you suffer from severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
Talk to your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking olmesartan/hydrochlorothiazide. Your doctor will decide whether to continue treatment. Do not stop taking olmesartan/hydrochlorothiazide on your own.
Olmesartan/hydrochlorothiazide may cause an increase in blood fat and uric acid levels (which can cause gout - painful swelling of the joints). Your doctor will probably want to do a blood test from time to time to check for these possible changes.
Olmesartan/Hydrochlorothiazide Krka may cause a change in the levels of certain chemicals in the blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check for this possible change. Some signs of electrolyte changes are: thirst, dry mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling of weakness, slowness, tiredness, drowsiness, or restlessness, nausea, vomiting, decreased need to urinate, rapid heartbeat. Tell your doctor if you notice any of these symptoms.
As with any other medicine that lowers blood pressure, excessively low blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. That's why your doctor will closely monitor your blood pressure.
If you are scheduled to have parathyroid function tests, you should stop taking olmesartan/hydrochlorothiazide before the tests.
Athletes are informed that this medicine may result in a positive doping test.
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking olmesartan/hydrochlorothiazide before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead. It is not recommended to take olmesartan/hydrochlorothiazide during pregnancy, and it must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after that time.
Children and adolescents
Olmesartan/hydrochlorothiazide is not recommended for children and adolescents under 18 years of age.
Other medicines and Olmesartan/Hydrochlorothiazide Krka
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist about any of the following medicines:
Taking Olmesartan/Hydrochlorothiazide Krka with food and drink
Olmesartan/Hydrochlorothiazide Krka can be taken with or without food.
Be careful when drinking alcohol while taking olmesartan/hydrochlorothiazide, as some people feel faint or dizzy. If this happens, do not drink any alcohol, including wine, beer, or drinks with alcohol.
Black patients
As with other similar medicines, the blood pressure-lowering effect of olmesartan/hydrochlorothiazide is somewhat less in black patients.
Pregnancy and breastfeeding
Pregnancy
You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking olmesartan/hydrochlorothiazide before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead. Olmesartan/hydrochlorothiazide is not recommended during pregnancy, and must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after that time.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. Olmesartan/hydrochlorothiazide is not recommended during breastfeeding. Your doctor may choose another treatment if you want to continue breastfeeding.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel drowsy or dizzy while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have gone away. Talk to your doctor.
Always take this medicine exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.
The recommended dose isone Olmesartan/Hydrochlorothiazide Krka 20 mg/12.5 mg tablet per day. If your blood pressure is not controlled adequately, your doctor may change the dose to one Olmesartan/Hydrochlorothiazide Krka 20 mg/25 mg tablet per day.
Take the tablet with water. If possible, you should take your dose at the same time each day, for example, at breakfast time. It is important that you keep taking olmesartan/hydrochlorothiazide until your doctor tells you to stop.
If you take more Olmesartan/Hydrochlorothiazide Krka than you should
If you take more tablets than you should or if a child accidentally takes one or more tablets, contact your doctor or go to the nearest hospital emergency department immediately and take the medicine pack with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, stating the medicine and the amount taken.
If you forget to take Olmesartan/Hydrochlorothiazide Krka
If you forget to take a dose, take your normal dose the next day as usual. Do not take a double dose to make up for forgotten doses.
If you stop taking Olmesartan/Hydrochlorothiazide Krka
It is important to continue taking olmesartan/hydrochlorothiazide unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
However, the following adverse effects may be serious:
Olmesartan/Hydrochlorothiazide Krka is a combination of two active ingredients, and the following information describes the adverse effects reported so far with the combination olmesartan/hydrochlorothiazide (in addition to those already mentioned) and, secondly, the known adverse effects of the two active ingredients separately.
These are other known adverse effects of olmesartan/hydrochlorothiazide so far:
If these effects occur, they are often mild and it is not necessary to interrupt treatment.
Common adverse effects (may affect up to 1 in 10 people):
Dizziness, weakness, headache, fatigue, chest pain, swelling of ankles, feet, legs, hands, or arms.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid and intense heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps, and muscle pain, joint pain, arm and leg pain, back pain, erection problems in men, blood in urine.
Also, some changes in blood test results have been observed, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased creatinine, increased or decreased potassium levels in the blood, increased calcium levels in the blood, increased blood sugar, increased liver function test values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Rare adverse effects (may affect up to 1 in 1,000 people):
Feeling of discomfort, changes in consciousness, skin swelling (hives), acute kidney failure.
Also, some changes in blood test results have been observed, including:
Increased blood urea nitrogen, decreased hemoglobin, and hematocrit values. Your doctor will monitor you with a blood test and tell you if you need to take any action.
Additional adverse effects reported with the use of olmesartan medoxomil or hydrochlorothiazide alone, but not with olmesartan/hydrochlorothiazide, or at a higher frequency:
Olmesartan medoxomil:
Common adverse effects (may affect up to 1 in 10 people):
Bronchitis, cough, nasal congestion or secretion, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, joint or bone pain, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.
Also, some changes in blood test results have been observed, including:
Increased levels of fat in the blood, increased urea or uric acid in the blood, increased liver or muscle function.
Uncommon adverse effects (may affect up to 1 in 100 people):
Rapid allergic reactions that can affect the whole body and cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, angina (chest pain or discomfort known as angina pectoris), feeling of discomfort, allergic skin rash, itching, exanthema (skin rash), skin swelling (hives).
Also, some changes in blood test results have been observed, including:
Decreased number of a type of blood cells called platelets (thrombocytopenia).
Rare adverse effects (may affect up to 1 in 1,000 people):
Kidney function deterioration, lack of energy, intestinal angioedema: swelling in the intestine with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Also, some changes in blood test results have been observed, including:
Increased potassium in the blood.
Hydrochlorothiazide:
Very common adverse effects (may affect more than 1 in 10 people):
Changes in blood tests, including:
Increased fat in the blood and uric acid levels.
Common adverse effects (may affect up to 1 in 10 people):
Feeling of confusion, abdominal pain, stomach discomfort, feeling of swelling, diarrhea, nausea, vomiting, constipation, glucose in urine.
Also, some changes in blood test results have been observed, including:
Increased creatinine, urea, calcium, and sugar levels in the blood, decreased chloride, potassium, magnesium, and sodium levels in the blood. Increased serum amylase (hyperamylasemia).
Uncommon adverse effects (may affect up to 1 in 100 people):
Decreased or lost appetite, severe breathing difficulties, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions due to light sensitivity, itching, purple spots or patches on the skin due to small hemorrhages (purpura), skin swelling (hives).
Rare adverse effects (may affect up to 1 in 1,000 people):
Inflammation and pain of the salivary glands, decreased number of white blood cells, decreased number of platelets in the blood, anemia, bone marrow depression, restlessness, depression, sleep problems, feeling of loss of interest (apathy), tingling and numbness, seizures (convulsions), yellowish perception of objects when looking at them, blurred vision, dry eyes, irregular heartbeat, inflammation of blood vessels, blood clots (thrombosis or embolism), lung inflammation, fluid accumulation in the lungs, pancreatitis, jaundice, infection in the gallbladder, symptoms of lupus erythematosus such as skin rash, joint pain, and cold hands and fingers, allergic skin reactions, skin peeling, and blisters, non-infectious kidney inflammation (interstitial nephritis), fever, muscle weakness (sometimes causing movement disorders).
Very rare adverse effects (may affect up to 1 in 10,000 people):
Electrolyte imbalance that can cause an abnormally reduced level of chloride in the blood (hypochloremic alkalosis), intestinal obstruction (paralytic ileus), acute respiratory distress (signs include severe respiratory distress, fever, weakness, and confusion).
Adverse effects of unknown frequency (cannot be estimated from the available data):
Decreased vision or eye pain due to high blood pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma), skin and lip cancer (non-melanoma skin cancer).
Reporting of adverse effects:
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaram.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton after CAD. The expiration date is the last day of the month indicated.
Store in the original packaging to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. Deposit the packaging and medicines you no longer need at the SIGRE collection point in the pharmacy. Ask your pharmacist how to dispose of the packaging and medicines you no longer need. This will help protect the environment.
Composition of Olmesartan/Hydrochlorothiazide Krka
Appearance of the Product and Package Contents
Olmesartan/Hydrochlorothiazide Krka 20 mg/12.5 mg film-coated tablets are white to almost white, round, biconvex tablets, marked with a C1 on one face of the tablet, diameter 9 mm.
The film-coated tablets are available in cartons of 10, 14, 28, 30, 56, 60, 84, 90, 98, and 100 film-coated tablets.
Not all pack sizes may be marketed.
Marketing Authorization Holder
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Manufacturer
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
You can obtain further information on this medicine by contacting the local representative of the Marketing Authorization Holder:
KRKA Farmacéutica, S.L., C/ Anabel Segura 10, Pta. Baja, Oficina 1, 28108 Alcobendas, Madrid, Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Austria | Olmesartan/HCT Krka |
Belgium | Olmesartan/HCTZ Krka |
Cyprus | Olmesartan/Hydrochlorothiazide TAD |
Germany | Olmecor HCT |
Greece | Olelom HCT |
Denmark | Olmesartan medoxomil/hydrochlorothiazide Krka |
Spain | Olmesartan/Hidroclorotiazida Krka |
Finland | Olmesartan medoxomil/Hydrochlorothiazide Krka |
Croatia | Co-Olimestra |
Ireland | Olmesartan/Hydrochlorothiazide Krka |
Italy | Olmesartan medoxomil and Hydrochlorothiazide HCS |
Netherlands | Olmesartan medoxomil/Hydrochloorthiazide Krka |
Norway | Olmesartan medoxomil/Hydrochlorothiazide Krka |
Portugal | Olmesartan medoxomil + Hydrochlorothiazide Krka |
Date of the last revision of this leaflet: April 2025
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
The average price of OLMESARTAN/HYDROCHLOROTHIAZIDE KRKA 20 mg/12.5 mg FILM-COATED TABLETS in October, 2025 is around 10.1 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN/HYDROCHLOROTHIAZIDE KRKA 20 mg/12.5 mg FILM-COATED TABLETS – subject to medical assessment and local rules.